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Abstract
Background: TMEFF2 is a protein containing a single EGF-like domain and two follistatin-like modules. The biological
function of TMEFF2 remains unclear with conflicting reports suggesting both a positive and a negative association between
TMEFF2 expression and human cancers.
Methodology/Principal Findings: Here we report that the extracellular domain of TMEFF2 interacts with PDGF-AA. This
interaction requires the amino terminal region of the extracellular domain containing the follistatin modules and cannot be
mediated by the EGF-like domain alone. Furthermore, the extracellular domain of TMEFF2 interferes with PDGF-AA–
stimulated fibroblast proliferation in a dose–dependent manner. TMEFF2 expression is downregulated in human brain
cancers and is negatively correlated with PDGF-AA expression. Suppressed expression of TMEFF2 is associated with its
hypermethylation in several human tumor types, including glioblastoma and cancers of ovarian, rectal, colon and lung
origins. Analysis of glioma subtypes indicates that TMEFF2 hypermethylation and decreased expression are associated with
a subset of non-Proneural gliomas that do not display CpG island methylator phentoype.
Conclusions/Significance: These data provide the first evidence that TMEFF2 can function to regulate PDGF signaling and
that it is hypermethylated and downregulated in glioma and several other cancers, thereby suggesting an important role for
this protein in the etiology of human cancers.
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Introduction
TMEFF2, also known as tomoregulin [1], TPEF [2], HPP1 [3]
and TENB2 [4], encodes a transmembrane protein that contains a
single epidermal growth factor (EGF)-like domain and two
follistatin-like modules [1,4–6]. The biological function of
TMEFF2 remains elusive with conflicting reports from different
groups. Soluble forms of TMEFF2 extracellular domain have been
reported to weakly stimulate erbB-4/HER4 tyrosine phosphory-
lation in MKN 28 gastric cancer cells [1], and promote survival of
mesencephalic dopaminergic neurons in primary culture [6]. As
evidence for its positive role in cell proliferation, elevated
TMEFF2 expression has been associated with higher prostate
cancer grade and hormone independence by several groups
[4,7,8]. In contrast, others have reported down-regulation of
TMEFF2 in androgen-independent prostate cancer xenografts, as
well as growth inhibition induced by ectopic expression of
TMEFF2 in androgen-independent prostate cancer cell lines [5].
Moreover, the 59-region of TMEFF2 gene is frequently hyper-
methylated in some cancers [2,3,9–16], suggesting a possible
tumor suppressor role of TMEFF2 in these cancers.
Platelet-derived growth factors (PDGFs) not only play important
roles in developmental and physiological processes, but also are directly
implicated in human cancer and other proliferative disorders (reviewed
in [17] and [18]). The human genome contains four PDGF ligands,
PDGF-A, B, C and D, and two receptors, PDGFRaand PDGFRbAll
PDGFs can form functional disulfide-linked homodimers, while only
PDGF-A and B have been shown to form functional heterodimers.
PDGFRs also function as homo- and hetero-dimers that differ in their
affinities to different PDGF dimers (reviewed in [17] and [18]). The a
subunit of PDGFR has been shown to bind the PDGF-A, B and C
chains, whereas the b subunit is believed to bind only the B and D
chains. The biological responses induced by the different PDGF
ligands depend on the relative numbers of the receptor subunits on a
given cell type and the specific PDGF dimers present.
Follistatin module-containing proteins have been previously
shown to be able to bind and modulate the function of a variety
of growth factors including members of the transforming growth
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factor (VEGF) [19–24]. To date, however, no binding partner has
been reported for TMEFF2. In this report, we have identified
PDGF-AA as a growth factor that interacts with TMEFF2.
Moreover, we show that the extracellular domain of TMEFF2
interferes with PDGF-AA–stimulated fibroblast proliferation in a
dose–dependent manner. Our data provide the first evidence that
TMEFF2 can function to regulate PDGF signaling, and give new
mechanistic insights into the seemingly conflicting roles of TMEFF2
in human cancers. In addition, we show for the first time that the
expression of TMEFF2 is downregulated in glioma and several
other cancers and that this downregulation correlates with DNA
methylation. Together these data suggest an important role of
TMEFF2 in the development and progression of human cancers.
Results
The extracellular domain of TMEFF2 interacts with
PDGF-AA
TMEFF2 is predicted to contain a transmembrane (TM)
domain with an amino terminal (NT) signal peptide sequence
(SP) (Fig. 1A). Recombinant proteins containing the extracellular
domain (ECD) of TMEFF2 fused to a FLAG tag (TECD-FLAG)
or the Fc portion of the human immunoglobulin gamma (hFcc
(TECD-Fc) at the carboxy-terminus (CT) were expressed in
mammalian cells and purified from cell culture supernatants
(Fig. 1B). The purified TECD-FLAG and TECD-Fc ran at the
predicted ,55 kDa and ,70 kDa on SDS PAGE under reducing
conditions, respectively (Fig. 1c). NT sequencing of the purified
proteins revealed that the signal peptide was cleaved between
residues 40 and 41 in both recombinant proteins (Fig. 1D).
Since follistatin (FS) module-containing proteins have been
shown to interact with PDGF ligands [19], we examined the ability
of each of the 3 dimeric forms of PDGF ligands, PDGF-AA, BB and
AB, to interact with the ECD of TMEFF2 using Enzyme-Linked
ImmunosorbentAssays(ELISA). Usinga biotinylated anti-PDGF-A
antibody, we observed a dose-dependent binding when 1 to 10 ng/
ml of PDGF-AA was added to the immobilized TECD-FLAG. A
weak binding was detected using PDGF-BB and a biotinylated anti-
PDGF-B antibody, whereas no significant binding was detected for
PDGF-AB using the biotinylated anti-PDGF-A antibody (Fig. 2A).
While there was only a slight background binding between PDGF-
AA and the uncoated plastic wells, the binding of PDGF-AA to
immobilized TECD-FLAG was comparable to its binding to an
immobilized anti-PDGF antibody under the same conditions
(Fig. 2A). No specific binding was detected for a variety of other
proteins examined, including the EGF Receptor family members
(EGFR, HER2, HER3 or HER4) and the tumor necrosis factor
receptor (TNFR) fused to hFcc. In addition, no significant binding
was detected between the TMEFF2 ECDs themselves when
TECD-Fc was used as an analyte. As a positive control, an anti-
FLAG monoclonal antibody showed dose-dependent binding to the
TECD-FLAG coated wells Fig. 2B).
To confirm that the binding observed is indeed due to the
interaction between PDGF-AA and TMEFF2-ECD, we then
immobilized the PDGF ligands on the plates, and applied the
TMEFF2-ECD fused to a different tag, TECD-Fc, as an analyte.
Consistent with the results obtained with immobilized TECD-
FLAG, TECD-Fc exhibited significant dose-dependent binding
only to immobilized PDGF-AA, but not AB, BB, CC or DD
(Fig. 2C; supplemental Fig. S1A). Similar results were obtained
using the label free ForteBio platform (Menlo Park, CA) to
measure PDGF binding to biotinylated TMEFF2-FLAG immo-
bilized on the streptavidin-coated sensor. PDGF-AA showed the
strongest binding to TMEFF2 while PDGF-BB, AB, CC, and DD
showed greatly reduced affinities (data not shown). A recombinant
soluble PDGF receptor a extracellular domain (sRa), on the other
hand, showed dose-dependent binding to all 3 immobilized PDGF
dimers AA, AB and BB (supplemental Fig. S1B), whereas the
PDGF receptor bECD-Fc (PDGFRb-Fc) fusion protein was not
able to bind PDGF-AA (Fig. 2D), consistent with the reported
specificity of these receptors [25–27].
TMEFF2 interacts with PDGF-AA through its FS module-
containing region when expressed on the surface of
mammalian cells
To determine if the ECD of TMEFF2 can interact with PDGF-
AA when expressed on the surface of mammalian cells, we
transfected 293 cells with constructs containing the full-length
TMEFF2 (TMEFF2-FL), or a truncated TMEFF2 without the
intracellular domain (TMEFF2-DICD) (Fig. 3). PDGF-AA or
PDGF-AB was then added to the culture media and allowed to
bind to the cell surface for 30 minutes. Unbound PDGF ligands
were subsequently washed away and cell lysates were subjected to
immunoprecipitation with either a polyclonal antibody (pAb)
recognizing both PDGF-AA and AB dimers, or a pAb recognizing
the ECD of TMEFF2. As shown in Fig. 3 & supplemental Fig. S8,
an anti-PDGF-A antibody could detect the denatured PDGF-A
monomer in the anti-PDGF immunoprecipitates from cells
incubated with either PDGF-AA or PDGF-AB, suggesting that
both PDGF dimers bound to the cell surface, either through
interactions with specific receptors or extracellular matrix (ECM)
proteins. However, PDGF-A was detected in the anti-TMEFF2
immunoprecipitates only from cells incubated with PDGF-AA but
not from those incubated with PDGF-AB. In addition, PDGF-AA
was present in anti-TMEFF2 immunoprecipitates from cells
expressing either the full-length TMEFF2 or the ICD-truncated
TMEFF2. This is consistent with the ELISA result showing that
PDGF-AA but not PDGF-AB exhibited dose-dependent binding
to the ECD of TMEFF2.
TMEFF2 contains 2 FS modules and an EGF-like domain. To
dissect which domains of TMEFF2 are involved in its interaction
with PDGF-AA, we made Herpes simplex type 1 glycoprotein D
(gD)-epitope tagged deletion mutants of TMEFF2 and examined
their ability to bind PDGF-AA when expressed on the surface of
293 cells (Fig. 4 & supplemental Fig. S8). As expected, PDGF-AA
co-immunoprecipitated with gD-tagged full-length TMEFF2 by
an anti-gD monoclonal antibody. However, when gD-tagged
TMEFF2 mutants lacking either the NT FS I (gD-TMEFF2-DFS
I) or both of the FS modules (gD-TMEFF2-DFS I/II) were
immunoprecipitated with the same anti-gD antibody, no PDGF-
AA was brought down, although both mutant TMEFF2 proteins
were brought down in the immunoprecipitates. FACS analysis also
confirmed membrane expression of all 3 gD-tagged proteins
(Supplemental Fig. S2). This suggests that NT regions containing
the FS I domain are required for the PDGF-AA interaction,
whereas EGF domain alone is insufficient for this interaction.
Consistent with this result, a recombinant His-tagged tandem-
array of the EGF domain of TMEFF2 also failed to show specific
binding to PDGF-AA–coated plates by ELISA (data not shown).
TMEFF2 modulates PDGF-stimulated proliferation of NR6
fibroblasts
PDGF ligands are potent mitogens of connective tissue cells,
including fibroblasts, smooth muscle cells, chondrocytes, and some
endothelial cells [17,28,29]. The finding that TMEFF2 interacts
with PDGF-AA at ng/ml concentrations of both recombinant
TMEFF2 Regulates PDGF Signaling
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possibility that TMEFF2 may regulate PDGF-AA signaling. We
first asked whether PDGFRa, the only receptor that binds PDGF-
AA, could compete with TECD for PDGF-AA binding. As shown
in Supplemental Fig. S1C, TECD-Fc binding to the PDGF-AA
coated plate was blocked by the soluble extracellular domain of
PDGFRa,s R a, in a dose dependent manner, indicating that
TMEFF2 ECD and sRa bind to PDGF-AA at overlapping sites.
We next examined the effect of TMEFF2-ECD on PDGF
stimulated proliferation. The murine fibroblast cell line NR6
expresses both PDGF receptors a and b [30], and exhibits dose-
dependent proliferation in response to PDGF-AA or PDGF-AB as
measured by BrdU incorporation (Fig. 5A, C). When 10 ng/ml
PDGF-AA was added in the presence of increasing concentrations
of Fc-tagged TECD, BrdU incorporation was inhibited in a dose-
dependent manner at concentrations between 0.6 and 2,000 ng/
ml of TECD-Fc (Fig. 5B). This effect was similar to that of sRa
which also inhibited PDGF-AA–induced BrdU incorporation at a
similar concentration range, albeit with a slightly higher efficiency.
PDGF-AB–induced BrdU incorporation, on the other hand, was
not affected by TECD-Fc under the same conditions (Fig. 5D).
Interestingly, sRa also had little effect on PDGF-AB–induced
proliferation, even though consistent with previous reports [31],
PDGF-AB could bind sRawith an affinity similar to PDGF-AA
(Supplemental Fig. S1B). This may be due to the ability of PDGF-
AB to bind to all 3 PDGFR dimers, aa, ab or bb [26], whereas
PDGF-AA can signal only through PDGFR aa dimers.It is
possible that PDGF-AB may have a higher affinity for the native
Figure 1. Expression and purification of recombinant ECD of TMEFF2. (A) Hydropathy plot of TMEFF2 protein based on the algorithm of
Kyte and Doolittle [53] and the predicted domain structure based on NT sequencing of the recombinant TECD in this study and Horie et al., 2000 [6].
SP, signal peptide; FS I, follistatin-like domain I; FS II, follistatin-like domain II; EGF, epidermal growth factor-like domain; TM, transmembrane domain;
N-Gly, potential sites for N-linked glycosylation; GAG, potential site of glycosaminoglycan attachment. (B) Schematic representation of the
recombinant TECD-FLAG and TECD-Fc fusion proteins aligned with the full length TMEFF2 (TMEFF2-FL). (C) Purified TECD-FLAG and TECD-Fc were
analyzed by SDS-PAGE under reducing conditions with Coomassie blue staining. (D) NT sequencing of the purified TECD-FLAG and TECD-Fc revealed
the cleavage site of the signal peptide. The amino acid sequence identified by NT sequencing is underlined. Arrowhead indicates the signal peptide
cleavage site.
doi:10.1371/journal.pone.0018608.g001
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more abundant PDGF receptor ab dimers and/or PDGF receptor
bb dimers on these cells.
TMEFF2 expression is downregulated in brain cancers
and is negatively correlated with PDGF-A expression
The 59-region of TMEFF2 gene is frequently hypermethylated
in some cancers [2,3,9–16], suggesting a possible tumor suppressor
role for TMEFF2 in these cancers. To compare the expression
levels of TMEFF2 in human tissues, we analyzed Affymetrix
microarray data obtained from GeneLogic, Inc. (Gaithersburg,
MD) containing multiple human tumor and normal tissue samples.
Highest levels of TMEFF2 expression were found in prostate and
brain tissues (Supplemental Fig. S3, S4). In situ hybridization
experiments confirmed high levels of TMEFF2 mRNA expression
in normal adult and fetal central nervous systems, as well as both
malignant and non-malignant prostate tissues (Supplemental Fig.
S5). The mean expression level of TMEFF2 is significantly higher
in prostate cancer tissues compared to normal prostate tissues
(Fig. 6A; Supplemental Fig. S3, S4), consistent with previous
reports [7]. In contrast, TMEFF2 exhibits significantly lower mean
levels of expression in malignant brain samples, especially in
glioblastomas (GBMs), compared to normal brain tissues (Fig. 6B;
Supplemental Fig. S3, S4). Most other tissues express TMEFF2 at
much lower levels than brain and prostate. Several tissues also
show a trend of decreased expression in cancers, such as
colorectal, esophagus and stomach, with statistically significant
difference in colorectal cancer samples compared to normal colon
tissues (Supplemental Fig. S3, S4). These data are consistent with a
possible tumor suppressor role of TMEFF2 in these tissues.
High grade gliomas (HGGs) have been classified into three
molecular subtypes based on similarity to defined expression
signatures: Proneural (PN), Proliferative (Prolif) and Mesenchymal
(MES) [32]. The Proneural subtype expresses genes associated
with normal brain and the process of neurogenesis. This subtype
has been associated with a better prognosis [32], and has recently
been linked to a subset of tumors exhibiting a glioma-CpG island
methylator phenotype (G-CIMP) and isocitrate dehydrogenase 1
Figure 2. Binding of PDGF ligands and other recombinant proteins to immobilized TECD-FLAG (A,B) and binding of TECD-Fc to
immobilized PDGF ligands (C,D). (A) Binding of dimeric PDGF ligands to TECD-FLAG coated wells. PDGF-AA, AB or BB were applied to TECD-
FLAG coated wells (solid symbols) or blank wells (open symbols) and detected with biotinylated anti-PDGF-A (for PDGF-AA & AB) or PDGF-B (for
PDGF-BB) antibodies followed by streptavidin-HRP. Anti-PDGF pAb coated wells were used as a positive control for PDGF-AA binding (x). (B) Binding
of six recombinant Fc-tagged ECDs and an anti-FLAG mAb to TECD-FLAG coated wells. HRP-conjugated anti-mouse and anti-human Fcc were used to
detect anti-FLAG mAb and Fc-tagged proteins, respectively. (C) TECD-Fc was applied to wells coated with PDGF-AA, AB or BB and detected with HRP-
conjugated anti-human Fcc.( D) TECD-Fc and other Fc–tagged ECD of various transmembrane proteins were applied to PDGF-AA coated wells and
detected with HRP-conjugated anti-human Fcc. TNFR, tumor necrosis factor receptor; PDGFRb, PDGF receptor b; mOX40, murine OX40. Error bars
represent standard deviations between duplicates. Representative graphs of at least three independent experiments are shown.
doi:10.1371/journal.pone.0018608.g002
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subtypes are of poorer prognosis [32], and are characterized by a
resemblance to either highly proliferative cell lines or tissues of
mesenchymal origin, with gene expression programs indicative of
cell proliferation or angiogenesis, respectively. Microarray analysis
of TMEFF2 in a set of 36 HGG samples that included 12
prototypical cases of each subclass [32,34] revealed significantly
higher levels of TMEFF2 expression in the PN subclass than the
Prolif and MES subclasses (Fig. 6C). Interestingly, PDGF-A
showed an almost mirror-image, opposite trend with the highest
expression in the MES subclass (Fig. 6D). Such a trend was not
observed for PDGF-B in these samples (data not shown). Further
analysis of microarray data in 76 HGG samples from M.D.
Anderson Cancer Center (MDA) and 57 HGG samples from
University of California San Francisco (UCSF) suggests a negative
correlation between TMEFF2 and PDGF-A expression in both
sets of samples (Fig. 6E). These data are consistent with the
hypothesis that PDGF-AA may be an important growth factor
required for the development of non-PN HGGs, and that
TMEFF2 expression may be selected against in these HGGs that
are dependent on PDGF-AA signaling.
TMEFF2 is hypermethylated in multiple tumor types with
its expression negatively correlated with methylation
levels
Hypermethylation of the TMEFF2 gene in human cancers has
been reported in several tissues including colorectal, gastric and
esophageal cancers [2,3,9–12,16]. However, these tissues express
very low levels of TMEFF2 even in normal samples, making the
significance of gene suppression less clear in these tumors. Since
the methylation status of TMEFF2 has not been reported in
glioma and most other tissues, we analyzed all publicly available
data from The Cancer Genome Atlas (TCGA) with results on both
Agilent expression and Infinium methylation arrays [35]. Of the
seven tumor types where these data are currently available, only
glioblastoma, and occasionally ovarian and rectal cancer samples
show significant levels of TMEFF2 expression (Fig. 7). All samples
with high levels of TMEFF2 expression correspond to low CpG
island methylation states, while samples with a methylation beta
value of greater than 0.1 have a suppressed expression of
TMEFF2, which is especially apparent in GBM samples (t-test
p-value 4610
214). TMEFF2 expression is barely detectable in
almost all colon adenocarcinoma, rectal adenocarcinoma, lung
adenocarcinoma and lung squamous cell carcinoma samples.
While the majority of these tumor samples show methylation beta
values greater than 0.1, there are insufficient data available to
determine whether different thresholds of methylation beta values
exist in different tumor types for suppressed TMEFF2 expression,
or other mechanisms exist to suppress its expression. Neverthe-
less, taken together with other published reports of TMEFF2
methylation in other tumor types, these data are consistent with
the hypothesis that TMEFF2 is silenced through DNA methyla-
tion in a significant proportion of human cancers, including
glioma and cancers of ovarian, rectal, colon and lung origins.
Figure 3. Co-immunoprecipitation of PDGF-AA with full-length or intracellular domain–truncated TMEFF2 expressed on the surface
of 293 cells. Multiple bands of TMEFF2-FL and TMEFF2-DICD were detected by the anti-TMEFF2 mAb due to different degrees of glycosylation and
proteoglycan attachment [4]. mAb, mouse monoclonal antibody; pAb, rabbit polyclonal antibody; Ig LC, light chain of the Ab used for the
immunoprecipitation.
doi:10.1371/journal.pone.0018608.g003
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methylation alterations, referred to as G-CIMP, have been
identified in the context of TCGA GBM samples [33].
Interestingly, G-CIMP-positive tumors belong to a subset of
Proneural tumors and are closely associated with IDH1 mutation.
These tumors have a favorable prognosis within GBMs as a whole
and also within the Proneural subset. To understand the
relationship between TMEFF2 methylation and the G-CIMP
signature, we compared the TMEFF2 methylation status against
the set of TCGA GBM samples with available G-CIMP and IDH1
mutation information. Of the TCGA samples analyzed by
Noushmehr et al. [33], 88 overlapped with the samples that we
analyzed using the publicly available dataset. 76 of these were G-
CIMP-negative and 12 were G-CIMP-positive. All 76 G-CIMP-
negative samples were negative for the IDH1 mutation, while all
12 G-CIMP-positive samples were positive for the IDH1
mutation. Strikingly, tumors with a greater than 0.1 TMEFF2
methylation beta value are found exclusively within the non-G-
CIMP and non-IDH1-mutant category (Fig. 8A & B). Thus,
TMEFF2 does not belong to the reported G-CIMP loci; in
contrast, there is a strong anti-correlation between TMEFF2
hypermethylation and G-CIMP-positive or IDH1 mutation status.
That TMEFF2 hypermethylation is not found in the G-CIMP
and IDH1-mutant GBM samples is consistent with our observa-
tion that higher levels of TMEFF2 are associated with the
Proneural HGGs, the subclass that the G-CIMP tumors belong to,
while suppressed expression of TMEFF2 is associated with the
Proliferative and Mesenchymal subclasses of HGGs (Fig. 6C).
Therefore, we further analyzed the relationship between TMEFF2
methylation status and the molecular subtypes of the TCGA GBM
samples. Using an unsupervised approach to classify data from
TCGA, Verhaak et al. described 4 GBM transcriptomal subtypes,
termed Proneural, Neural, Mesenchymal and Classical [36]. As
recently reviewed in Huse et al. [37], comparison of classification
schemes of Verhaak et al. and Phillips et al. [32] reveals a large
degree of agreement in assignment of samples to Proneural and
Mesenchymal subtypes, while the other expression subtypes are
less well resolved. Therefore, we assigned ‘‘Proneural’’ only to
those GBM samples that are classified as Proneural by both
Phillips and Verhaak schemes, and ‘‘Mesenchymal’’ only to those
classified as Mesenchymal by both schemes ([37]; C. Brennan,
personal communication). All other samples are designated as
‘‘Other’’. As expected, TMEFF2 methylation beta values.0.1 are
almost exclusively observed in a subset of non-Proneural GBM
samples, including both Mesenchymal and Other subtypes
(Fig. 8C). Thus, TMEFF2 hypermethylation anti-correlates with
the Proneural signature in GBMs. Consistent with the observation
in HGG samples shown above, Proneural GBMs express the
lowest levels of PDGF-A, compared to other GBMs (Fig. 8D).
Moreover, a strong anti-correlation also exists between PDGF-A
and TMEFF2 expressions in the TCGA GBM samples (Fig. 8E).
Discussion
Follistatin domain–containing proteins have been shown to
interact with growth factors or their binding partners and
modulate their signaling [19,24,38]. For example, the follistatin
domain–containing ECM–associated glycoprotein SPARC/osteo-
nectin was reported to interact with PDGF-AB and BB (but not
AA) and inhibit the binding of these ligands to their cognate
Figure 4. Interaction of PDGF-AA with gD-tagged deletion mutants of membrane–bound TMEFF2. Multiple bands of TMEFF2-FL and
TMEFF2-DFS I were detected by the anti-TMEFF2 mAb due to different degrees of glycosylation and proteoglycan attachment [4].
doi:10.1371/journal.pone.0018608.g004
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TMEFF2 selectively interacts with PDGF-AA via its follistatin
domain–containing extracellular regions, and modulates PDGF-
AA–stimulated proliferation of NR6 fibroblasts. Interestingly, both
shedding of the extracellular domains of TMEFF2 [39], and a
truncated splice variant of TMEFF2 encoding a secreted protein
without the EGF-like and the transmembrane domains [40], have
been identified in cells, suggesting a possible functional role of the
extracellular region containing the follistatin domains independent
of the intracellular and transmembrane regions.
First identified in a search for serum factors that stimulate the
proliferation of arterial smooth muscle cells [41], PDGFs have
been shown to direct a variety of cellular responses including
proliferation, survival, migration, and the deposition of ECM and
tissue remodeling factors (reviewed in [17] and [18]). Of the genes
encoding the four PDGF ligands and their two receptor chains,
mouse knockout studies have suggested that PDGF-B and
PDGFRß are essential for the development of support cells in
the vasculature, whereas PDGF-A and PDGFRa are more
broadly required during embryogenesis, with essential roles in
central nervous system, neural crest and organ development
(reviewed in [18]). PDGFs have also been implicated in the
etiology of human cancers. Both PDGFs and PDGFRs are
upregulated in human gliomas and astrocytomas, and PDGFRa
mRNA expression levels are higher in more advanced forms of
gliomas than in less malignant glial tumors [42,43]. Elevated levels
of PDGF-A and PDGFRa proteins have also been observed in
human prostate carcinomas [17,44,45]. In human gastric cancers,
high levels of PDGF-A correlate with high-grade carcinomas and
reduced patient survival [46]. Pdgfra-activating mutations have also
been identified in a subset of human gastrointestinal stromal
tumors [47]. Interestingly, we and others have observed highest
levels of TMEFF2 expression in the central nervous system and
the prostate amongst normal human tissues (Supplementary
Figures S3, S4, S5 and [7]). Conversely, lower levels of TMEFF2
are found in multiple cancer tissues, especially in the malignant
brain and colorectal samples, when compared to normal tissues.
The significance of the previously reported hypermethylation of
TMEFF2 gene in human cancers including colorectal, gastric and
esophageal cancers [2,3,9–12,16] is confounded by the low levels
of TMEFF2 expression in normal tissues of these origins. Here we
report hypermethylation of TMEFF2 in several additional tumor
types, including GBM, where a clear down-regulation is observed
compared to high levels of TMEFF2 expression in normal brain
tissues. We show that expression of TMEFF2 negatively correlates
with its methylation levels in GBM and several other tumor types,
Figure 5. TECD-Fc interferes with PDGF-AA–stimulated proliferation of NR6 cells. (A)&( C) Dose-dependent stimulation of BrdU
incorporation by PDGF-AA and PDGF-AB in NR6 cells. (B)&( D) Effects of increasing concentrations of TECD-Fc (filled bars) or PDGF sRa (open bars) on
10 ng/ml PDGF-AA (B) or PDGF-AB (D) stimulated BrdU incorporation.
doi:10.1371/journal.pone.0018608.g005
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these tissues. In contrast, the mean TMEFF2 mRNA expression is
elevated in prostate cancer tissues, especially non-metastatic
prostate cancer tissues, compared to normal prostates, suggesting
a possible tissue and cell context-dependent dual function of
TMEFF2 in human cancers.
We have found that TMEFF2 hypermethylation is associated
with non-Proneural subtypes of GBMs, in contrast with G-CIMP
methylation and IDH1 mutation status, which are associated with
the Proneural subtype and lower-grade gliomas. These associa-
tions are consistent with our finding of higher levels of TMEFF2
expression in the Proneural subtype. Moreover, we observe an
exclusivity relationship between TMEFF2 hypermethylation and
G-CIMP methylation, in that none of our samples show both types
of methylation patterns. These data suggest that TMEFF2 is
preferentially hypermethylated and suppressed in a subset of non-
Proneural and non-G-CIMP HGGs, and that TMEFF2 methyl-
ation may be associated with worse prognosis.
Figure 6. TMEFF2 expression is downregulated in glioma. (A) Affymetrix signal intensity of TMEFF2 expression in prostate cancer vs non-
cancerous tissues based on GeneLogic data. (B) Affymetrix signal intensity of TMEFF2 expression in normal brain vs brain cancer tissues based on
GeneLogic data. Each open circle in (A)&( B) represents one patient sample. Box-and Whisker plots are also included under the raw data to indicate
the mean and the 25th and 75th percentile ranges. The whiskers are drawn at 1.5 times the interquartile range from the box. (C)&( D) Normalized
signals of TMEFF2 (C) and PDGF-A (D) mRNA expression in Proneural (PN), Proliferative (Prolif), or Mesenchymal (MES) subtypes of 36 glioma samples.
Mean signals for each subtype are shown as insets. * p#0.05; **, p#0.005. (E) TMEFF2 expression is negatively correlated with PDGF-A expression in
133 (76 MD Anderson and 57 UCSF) HGG samples (Pearson correlation coefficient r=20.37). Each axis represents normalized signals of each gene. All
expression data were obtained using Affymetrix HG-U133A and HG-U133B GeneChips from probe 223557_s_at for TMEFF2 and 205463_s_at for
PDGF-A, respectively.
doi:10.1371/journal.pone.0018608.g006
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18608Figure 7. Expression vs. methylation status of TMEFF2 in 7 human tumor types. Methylation levels are plotted on the x-axis by averaging
the beta values of the two Infinium probes, cg06856528 and cg18221862, and mRNA expression levels obtained on the Agilent chip are plotted on
the y-axis.
doi:10.1371/journal.pone.0018608.g007
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PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18608We also observed an anti-correlation between TMEFF2
expression and PDGF-A expression in the GBM and HGG
samples, with lowest levels of PDGF-A expression observed in the
Proneural subtype compared to other subtypes. Interestingly,
despite the high levels of TMEFF2 and low levels of PDGF-A
expression, PDGFRa amplification appears to be associated with
the Proneural signature of GBM, which may also display elevated
PDGF signaling signature through increased PDGF-B protein
levels and elevated phosphorylation of PDGFRb [36,48]. In fact, a
broad range of human gliomas display altered PDGF pathway
activity, strongly suggesting that this signaling axis plays central
roles in the events underlying gliomagenesis [49]. It is possible that
TMEFF2 serves as a tumor suppressor in normal brain by
inhibiting signaling via PDGF-AA. Hypermethylation and down-
regulation of TMEFF2 may facilitate tumorigenesis in the tumors
that express high levels of PDGF-A by releasing this inhibition.
This mechanism of tumorigenesis can only function when PDGF-
AA is present and may select for both low TMEFF2 and high
PDGF-A expression. Of note, Verhaak et al. reported PDGF-A
overexpression as one of the gene signatures in the ‘‘Classical’’
subtype of GBMs [36]; this subtype also exhibited the highest
proportion of samples with TMEFF2 hypermethylation in our
analysis (Supplemental Fig. S7). In contrast, Proneural and other
tumors with low PDGF-A expression may utilize or be selected for
a different mechanism to activate PDGF signaling despite the low
levels of PDGF-A expression, such as upregulation of PDGF-B
[48] or amplification of PDGFR [36], without the repression of
TMEFF2. It should be noted that PDGFRa can be activated by
ligands other than PDGF-AA, such as PDGF-BB and PDGF-CC,
therefore can signal in the absence of PDGF-A.
Our findings not only suggest a connection between the role of
TMEFF2 in PDGF signaling and the potential tumor suppressor
function of TMEFF2, but also provide possible explanations for
the seemingly conflicting roles of TMEFF2 in human cancers. It
was previously reported that soluble forms of TMEFF2 extracel-
lular domain could weakly stimulate erbB-4/HER4 tyrosine
phosphorylation in MKN 28 gastric cancer cells [1], and promote
survival of mesencephalic dopaminergic neurons in primary
culture [6]. Although we did not detect a direct interaction
between the EGF domain of TMEFF2 and HER4, it is
conceivable that the EGF-like domain might have growth factor-
like functions opposite to its follistatin domains. Alternatively, the
interaction between TMEFF2 and PDGF-AA may either function
to sequester the active PDGF ligand away from its receptor, or act
as a carrier to concentrate or stabilize the PDGF ligand,
depending on the local concentrations of these proteins in different
cellular contexts.
Materials and Methods
Cell culture and reagents
The HEK 293 (Genentech, [50]) and NR6 cell lines [51] were
maintained at 37uC and 5% CO2 in DMEM/Ham’s F-12 (1:1)
containing 10% fetal bovine serum (FBS) and RPMI 1640
containing 10% calf serum, respectively. Recombinant human
PDGF-AA, AB, BB, CC and DD, recombinant human PDGF
receptor a extracellular domain (PDGF sRa), recombinant human
PDGFRb-Fc, goat anti-human PDGF, and biotinylated goat anti-
human PDGF-A and PDGF-B antibodies were obtained from
R&D Systems (Minneapolis, MN). Rabbit anti-PDGF-A polyclon-
al antibody was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Mouse anti-FLAG antibody was obtained from Sigma
(St. Louis, MO). Other recombinant proteins and antibodies were
generated at Genentech.
Generation of the various deletion and fusion TMEFF2
constructs
The full-length TMEFF2 open reading frame (GenBank Acces-
sion No. NM_016192) was cloned into a modified pRK vector
containing a CMV promoter. The FLAG-tagged extracellular
domain of TMEFF2 (TECD) was cloned into the same vector by
PCR amplification using forward primer 59- CTATCGATCTA-
TCGATATGGTGCTGTGGGAGT-39 and reverse primer 59-
GACTCTAGAGTCACTTGTCATCGTCGTCCTTGTAGTC-
GGCGCGCCACTTTTTTTCACAGTGTT-39 with the FLAG
tag (amino acid sequence WRADYKDDDDK) fused in-frame to
the CT of the end of the EGF domain. TECD-Fc was generated
similarly using the same forward primer and reverse primer 59-
CTGGGCGCGCCACTTTTTTTCACAGTGTT-39 and cloned
into the same vector containing the human Fcc sequence which
was fused in-frame 39 to the end of the EGF domain. The gD-
tagged full-length TMEFF2 was cloned into the same vector with a
59 gD tag (amino acid sequence KYALADASLKMADPNRFR-
GKDLPVLSGR) attached in-frame to the predicted start of the
mature protein. gD-TMEFF2-DFS I and TMEFF2-DFS I/II were
PRC amplified with the same reverse primer 59-CGACTCTA-
GATTAGATTAACCTCGTGGACGCT-39 and either 59-CTG-
CTCGAGTGTGATATTTGCCAGTTTGGTG-39 or 59-CTG-
CTCGAGACACCACATACCTTGTCCGGAAC-39 as forward
primer, respectively.
ELISA to measure binding between TMEFF2, PDGF and
other proteins
For the TMEFF2 coat format, MaxiSorp 96-well microwell
plates (Thermo Scientific Nunc, Roskilde, Denmark) were coated
with 1 mg/ml TECD-FLAG (Genentech) in 50 mM carbonate
buffer, pH 9.6, overnight at 4uC. Plates were washed with PBS,
pH 7.4, containing 0.05% polysorbate 20 and blocked with 0.5%
bovine serum albumin, 15 parts per million Proclin 300, in
phosphate buffered saline (PBS), pH 7.4 for 1 hour at room
temperature. Serially diluted PDGF-AA, PDGF-AB, PDGF-BB or
Fc-fusion proteins in PBS containing 0.5% BSA, 0.05%
polysorbate 20, and 15 parts per million Proclin 300 were added
to the plates and incubated for 2 hours. Bound PDGF was
detected by adding biotinylated goat anti-human PDGF-AA,
PDGF-AB or PDGF-BB to the plates and incubating for one hour,
followed by adding horseradish peroxidase (HRP) conjugated
streptavidin (GE Healthcare, Piscataway, NJ) and incubating for
30 min, with a wash step in between. Bound Fc-fusion protein was
detected by adding goat anti-human Fc-HRP (Jackson ImmunoR-
esearch, West Grove, PA). After a final wash, the substrate
3,39,5,59-tetramethyl benzidine (Kirkegaard & Perry Laboratories)
was added. The reaction was stopped by adding 1 M phosphoric
acid and absorbance was read at 450 nm on a Multiskan Ascent
reader (Thermo Scientific, Hudson, NH). The titration curves
Figure 8. Correlates of TMEFF2 methylation and expression in TCGA glioblastoma samples. (A) TMEFF2 methylation status vs. G-CIMP
status. (B) TMEFF2 methylation status vs. IDH1 mutation status. (C) TMEFF2 methylation status vs. GBM molecular subtypes. (D) PDGF-A expression vs.
GBM molecular subtypes. (E) TMEFF2 expression vs. PDGF-A expression [t-test p-value=6.6610
213 between PDGF-A expression levels in samples
with high TMEFF2 (expression value$10) vs. those with low TMEFF2 (expression value,10)].
doi:10.1371/journal.pone.0018608.g008
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fitting program (KaleidaGraph, Synergy software, Reading, PA).
For the PDGF coat format, plates were coated with 1 mg/ml
PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, or PDGF-DD.
Serially diluted TECD-Fc (Genentech) or other Fc-fusion proteins
were added to the plates. Bound protein was detected using goat
anti-human Fc-HRP (Jackson ImmunoResearch, West Grove, PA).
ELISA to measure binding of PDGF receptor a to PDGF
To measure binding of soluble PDGF receptor a to PDGF,
recombinant human PDGF receptor a extracellular domain
(PDGF sRa) was biotinylated using biotin-X-NHS (Research
Organics, Cleveland, OH). Serially diluted biotinylated human
recombinant PDGF sRa was added to PDGF-AA, PDGF-AB or
PDGF-CC coated wells. Bound receptor was detected using
streptavidin-HRP.
To measure blocking of TECD-Fc binding to PDGF-AA by
PDGF sRa, serially diluted PDGF sRa was pre-mixed with
TECD-Fc (final concentration 70 ng/ml) and added to the PDGF-
AA coated plate. Bound TECD-Fc was detected using goat anti-
human Fc-HRP.
Immunoprecipitation and Western blot
For binding of PDGF ligands to membrane-bound TMEFF2
proteins, 293 cells were transfected with the various TMEFF2
constructs and changed to fresh growth medium containing 5 mg/
ml PDGF-AA or AB 48 hours after transfection. After 30 minutes
of incubation unbound PDGF ligands were washed away with ice
cold PBS and cells were lysed in lysis buffer containing 50 mM
Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, protease
and phosphatase inhibitors, pre-cleared with protein G sepharose,
and immunoprecipitated with anti-TMEFF2, anti-PDGF, or anti-
gD antibodies. The immune complexes were dissociated with SDS
sample buffer with b-mercaptoethanol and resolved by 4–20%
Tris-Glycine SDS PAGE, transferred to nitrocellulose membranes,
and detected with the indicated antibodies using enhanced
chemiluminescence.
NR6 proliferation assays
The NR6 proliferation assay was carried out using a 5-Bromo-
29-deoxy-uridine (BrdU) labeling and detection kit (Roche). The
indicated concentrations of PDGF-AA or AB were added to
quiescent confluent cultures of NR6 cells in RPMI 1640
supplemented with 16Serum Replacement 1 (Sigma) on 96-well
microplates, either alone or after pre-mixing with increasing
concentrations of TECD-Fc or sRa for 1 hour at 37uC. After
18 hours at 37uC and 5% CO2, BrdU labeling solution was added
to each well and the subsequent labeling and detection were
carried out following the manufacturer’s protocols. BrdU incor-
poration was measured as absorbance at 405 nm with a reference
wavelength at 490 nm.
Microarray analysis
Gene expression profiling and analysis of microarray data were
performed as previously reported [32,52] using probe 223557_s_at
for TMEFF2 and 205463_s_at for PDGF-A, respectively. Signal
intensity values from Microarray Analysis Suite version 5 were
utilized with a scaling factor of 500 for all analysis of microarray
data. The raw Affymetrix data for TMEFF2 in the GeneLogic
tissues are given in Table S1. The microarray data for HGG
samples have been submitted to Gene Expression Omnibus
(GEO), and the accession number for the data series is GSE4271
[32]. All data are MIAME compliant.
Methylation and expression analysis of TCGA data
We obtained data from the Cancer Genome Atlas (TCGA) that
was publicly available as of July 29, 2010, on both the Illumina
Infinium methylation microarray and the Agilent G4502A
expression microarray. We correlated samples based on the
MAGE tables provided and found dual methylation and
expression measurements for 86 colon adenocarcinomas, 226
glioblastoma samples, 36 renal papillary cell carcinomas, 21 lung
adenocarcinomas, 69 lung squamous cell carcinomas, 535 ovarian
carcinomas, and 53 rectal adenocarcinomas.
Methylation was measured using the beta value taken from the
Level 2 files provided by TCGA. From the TCGA array
description files, we identified two CpG site methylation probes
for TMEFF2: cg06856528 and cg18221862. These probe sequenc-
es are located at (2204 to 2155) and (229 to +20) relative to the
translation start codon, within a CpG island described previously
[3]. We found correlations between the beta values for these probes
to be above 0.80 for the colon adenocarcinoma, lung adenocar-
cinoma, and lung squamous cell carcinoma data sets, but 0.73 for
gliomas, 0.67 for rectal adenocarcinomas, 0.62 for ovarian
carcinomas, and 0.25 for renal papillary cell carcinomas (Supple-
mental Fig. S6A). We used the average of the two beta values as our
estimate for methylation levels.
Expression was measured using the antilog of the log2 lowest
normalized values from the Level 2 files provided by TCGA. The
array description files showed three probes belonging to TMEFF2:
A_23_P125382, A_23_P125383, and A_23_P125387. Pairwise
correlations among these expression values were 0.94–0.95
(Supplemental Fig. S6B). We used the average of these probe
values as our estimate for expression levels. The probe A_23_
P113701 was used for PDGF-A expression.
TCGA samples having the same identifier as those reported by
Noushmehr et al [33] were used for comparison between
TMEFF2 methylation levels and their G-CIMP and IDH1 status.
The subtype classifications of TCGA GBM samples according to
either Phillips et al. or Verhaak et al. have been reported in
summary (Huse et al., 2011 [37]) and individual sample classi-
fications were kindly provided by Dr. Cameron Brennan. Tumors
classified as ‘‘Proneural’’ or ‘‘Mesenchymal’’ by both signatures
are assigned these two subtypes in Figures 8C and 8D, and all
other samples are classified as ‘‘Other’’.
Supporting Information
Table S1 Affymetrix signal intensity of TMEFF2 from Gene-
Logic tissues with probe 223557_s_at on HG-U133A and HG-
U133B GeneChips.
(XLS)
Figure S1 TECD-Fc selectively interacts with PDGF-AA.
(A) PDGF-AA, but not AB, BB, CC or DD, binds to TECD-Fc.
TECD-Fc was applied to wells coated with recombinant human
PDGF-AA, AB, BB, CC or DD and detected with HRP-
conjugated anti-human Fcc.( B)s R a binds to all three recombi-
nant human PDGFs: AA, AB and BB. Biotinylated recombinant
sRa (sRa-bio) was applied to wells coated with recombinant
human PDGF-AA, AB or BB and detected with streptavidin-
HRP. (C) 70 ng/ml TECD-Fc was mixed with increasing
concentrations of sRa and applied to PDGF-AA coated wells.
Binding between TECD-Fc and PDGF-AA was detected using
goat anti-human Fc-HRP.
(TIF)
Figure S2 gD-tagged TMEFF2 proteins are expressed on the
cell surface as detected by an anti-gD antibody. FACS analysis of
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PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18608293 cells expressing the gD-tagged full-length TMEFF2 or deletion
mutants lacking either FS I or both FS modules using anti-gD
mAb (black) and four mAbs (red, green, orange and blue)
recognizing the FS I module of TMEFF2. Biotinylated anti-mouse
IgG was used as a secondary reagent followed by streptavidin-PE.
Filled purple, no primary antibody control.
(TIF)
Figure S3 Comparative transcript expression profiles of
TMEFF2 in human tissues based on GeneLogic data. The mRNA
expression patterns for TMEFF2 across thousands of human
cancer (red) and normal (green) tissue specimens using probe
223557_s_at on chips HG-U133A and B are shown.
(TIF)
Figure S4 TMEFF2 expression is down-regulated in some
cancers. (A) Bar-graphs of mean TMEFF2 mRNA expression
levels in indicated tissues based on GeneLogic data. Error bars
represent standard errors of the mean. (B) Number of tissues
analyzed in each category. [N], Normal tissues; [C], Cancer
tissues; [M], metastatic tissues; * p,0.05 and ** p,0.005
compared to normal.
(TIF)
Figure S5 In situ hybridization (ISH) analysis of TMEFF2
mRNA expression in normal adult brain and cerebellum (A), fetal
spinal cord and spinal ganglion (B), non-malignant prostate (C)
and prostate cancer tissues collected on tissue microarrays (TMA)
(D). Upper panels, H & E stains; lower panels, ISH signals (white).
(TIF)
Figure S6 (A) Correlations between the beta values of two
TCGA array methylation probes for TMEFF2 in the tissues
analyzed: colon adenocarcinoma (coad), lung adenocarcinoma
(luad), lung squamous cell carcinoma (lusc), glioma (gbm), rectal
adenocarcinoma (read), ovarian carcinoma (ov), and renal
papillary cell carcinoma (kirp). (B) Pairwise correlations among
the three expression probes belonging to TMEFF2.
(TIF)
Figure S7 TMEFF2 methylation (A) vs. PDGF-A expression (B)
in GBM subtypes. Each GBM sample is classified according their
classification by both Verhaak and Phillips schemes (denoted as
Verhaak scheme:Phillips scheme).
(TIF)
Figure S8 (A) Efficiency of anti-TMEFF2 immunoprecipitation
of full-length or intracellular domain–truncated TMEFF2 ex-
pressed on 293 cells compared to inputs in the whole cell lysates
(WCL). (B) Efficiency of PDGF-A co-immunoprecipitation with
full-length TMEFF2 with or without a gD tag compared to 5 ng of
recombinant PDGF-AB or the amount of surface-bound PDGF-A
in the whole cell lysates (WCL).
(TIF)
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